Targeted Inhibition of LPL/FABP4/CPT1 fatty acid metabolic axis can effectively prevent the progression of nonalcoholic steatohepatitis to liver cancer. This evidence concerns the gene CPT1A and metabolic dysfunction-associated steatohepatitis.